Abstract
BACKGROUND Acute exacerbations of COPD are key events in the natural course of the patients illness, as they significantly impair the health condition, accelerate the deterioration of lung function, worsen the prognosis for the patient and account for the majority of the COPD-related healthcare costs. Particularly in patients with a pre-existing non-invasive ventilation (NIV) therapy, a reduction of exacerbation frequency is crucial, as they are at high risk for a lasting morbidity and increased mortality.
METHODOLOGY A prospective cohort study was conducted. Data from adult patients with the diagnosis COPD and existing High-Intensity NIV (HINIV) therapy from August 2021 to September 2023 was analyzed. Exacerbation history of moderate and severe exacerbations of the past 12 months and blood gases at initiation and during HINIV therapy were analyzed.
RESULTS 20 patients were included (mean age 69.2±9 years; 70% female). After initiation of HINIV therapy the frequency of exacerbation displayed a significant reduction from 1.5±0.9 to 0.5±0.5 per year (p<0.001). In addition, improvements in pCO2 (73.0±22.0 mmHg vs. 44.0±4.8 mmHg; p<0.001), the pH (7.33±0.1 vs. 7.42±0.0; p<0.001) and HCO3- (33.0±4.9 mmol/l vs. 27.9±3.2 mmol/l; p<0.001) were successfully demonstrated.
DISCUSSION The present study demonstrates the positive effects of high-intensity NIV on exacerbation rate, measured by the number of moderate and severe exacerbations in one year. Most significant effects were observed when patients had a high number of exacerbations before the initiation of NIV therapy.
What are the main findings?
A significant reduction in the number of exacerbations was demonstrated with HINIV.
There was a strong reduction in the frequency of exacerbations, especially in patients with a high frequency of exacerbations before the HINIV therapy was initiated.
What are the implications of the main findings?
The exacerbation history should be a more important factor in determining the indication for NIV therapy.
Further studies on the pathophysiological causes must follow in order to comprehensively assess the therapeutic effects of NIV.
Competing Interest Statement
GM, MB: no conflict of interests. MZ, MWS, DK, DSM, SBS received travel grants from companies dealing with mechanical ventilation products. DSM reports open research grant from Philips Respironics/USA. MZ, WW received speaking fees from companies dealing with mechanical ventilation products. The study group received open research grants from Weinmann/Germany, Vivisol/Germany, Loewenstein Medical/Germany, VitalAire/Germany, and Philips Respironics/USA. The authors report no other conflicts of interest in this work.
Funding Statement
The main study was financially supported by Loewenstein medical SE & Co. KG (Bad Ems, Germany) with an open research grant without influence on the study design. This additional detailed analysis was performed without separate financial support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study protocol was approved by the ethics committee of University Witten/Herdecke and was conducted in accordance to the ethical guidelines of the declaration of Helsinki (last revised in October 2013). Informed written consent was obtained from all patients.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The authors intend to share individual deidentified participant data with any other unfunded or funded research-related purpose under appropriate circumstances. Please contact the corresponding author for more information.
Abbreviations
- CHRF
- chronic hypercapnic respiratory failure
- EPAP
- Exspiratory positive airway pressure
- HINIV
- high-intensity NIV therapy
- IPAP
- Inspiratory positive airway pressure
- NIV
- Non-invasive ventilation